Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial
- Conditions
- Salvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib.MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- EUCTR2021-001841-11-ES
- Lead Sponsor
- MaaT Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 75
•Age = 18 years old
•Allo-HSCT with any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen.
•Acute GvHD episode with GI involvement per MAGIC guidelines (= grades II to IV), with or without involvement of other organs (Harris, Young, et al. 2016).
•Patients resistant to steroids AND either resistant to OR with intolerance to ruxolitinib:
Resistance to steroids is defined as any of the following:
Lack of improvement (i.e., no decrease in stage in at least 1 involved organ system) after = 5 days of treatment with CS at 2mg/kg/d methylprednisolone equivalent dose,
Progression (i.e., increase in any organ system or any new organ involvement) after = 3 days of treatment with CS at 2 mg/kg/d methylprednisolone equivalent dose,
Patients treated with 1 mg/kg/d of CS because the physician deemed they would not tolerate 2 mg/kg/d and who correspond to the definition of SR patients,
Patients who previously began CS therapy at a lower dose (at least 1 mg/kg/d methylprednisolone equivalent) for skin or upper GI GvHD but develop new GVHD in another organ system,
Patients who cannot tolerate corticosteroid tapering, i.e., begin of CS at 2.0 mg/kg/d, demonstrate response, but show disease progress before a 50% decrease from the initial starting dose of CS is achieved.
Resistance to ruxolitinib is defined as any of the following (Mohty et al. 2020):
Progression of GvHD compared to baseline after at least 5 days of treatment with ruxolitinib, based either on objective increase in stage/grade, or new organ involvement;
Lack of improvement in GvHD (partial response or better) compared to baseline after at least 14 days of treatment with ruxolitinib;
Loss of response, defined as objective worsening of GvHD determined by increase in stage, grade or new organ involvement at any time after initial improvement
Absence of complete response or very good partial response at day 28 after ruxolitinib
Intolerance to ruxolitinib is defined as:
GvHD manifestations that persist without improvement in patients who had grade 3 or higher treatment-emergent and ruxolitinib-attributed adverse event that did not resolve within 7 days of discontinuing ruxolitinib
•Signature of informed and written consent by the subject or by the subject’s legally acceptable representative for patients under guardianship or trusteeship.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 25
•Patients who had previously received other lines of systemic aGvHD treatment other than CS and ruxolitinib.
•Grade II-IV hyper-acute GvHD as defined by the MD Anderson’s criteria (Saliba et al. 2007) (aGvHD onset within 14 days after allo-HSCT)
•Overlap chronic GvHD as defined by the NIH Consensus Criteria (Jagasia et al. 2015)
•Relapsed/persistent malignancy requiring rapid immune suppression withdrawal
•Liver stage 4 and/or skin stage 4 aGvHD.
•Active uncontrolled infection according to the attending physician
•Severe organ dysfunction unrelated to underlying GvHD, including:
-Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GvHD and ongoing organ dysfunction, with the exception of Gilbert syndrome).
-Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months before Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support that requires therapy.
-Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
•Current or past veno-occlusive disease or other uncontrolled complication unless otherwise agreed in writing by the sponsor.
•Absolute neutrophil count <500/µL, confirmed within 3 days prior to pre-treatment start. Use of growth factor supplementation is allowed.
•Absolute platelet count < 10 000/µL, confirmed within 3 days prior to pre-treatment start. Use of platelet infusion is allowed.
•Patient with negative IgG EBV serology.
•Current or past evidence of toxic megacolon, bowel obstruction or gastrointestinal perforation.
•Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
•Known allergy or intolerance to trehalose or maltodextrin.
•Vulnerable patients such as: minors, persons deprived of liberty, persons in Intensive Care Unit unable to provide informed consent prior to the intervention.
•Females of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. Females of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from procreative sexual activity for the course of the study. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year.
Males should agree to abstain from procreative sexual activity starting with the first dose of study therapy through the end of the study.
•Other ongoing interventional protocol that might interfere with the current study’s primary endpoint.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method